On July 19, Amgen
- Per-share earnings jumped 43.9%, but watch out for stock options.
- Amgen's margins are deliciously high, something we like at the Fool.
(Figures in millions, except per-share data)
Income Statement Highlights (What's this?)
|
Q2 2005 Avg. Est. |
Q2 2005 |
Q2 2004 |
% Change |
|
|---|---|---|---|---|
|
Sales |
$2,990.0 |
$3,172.0 |
$2,585.0 |
+22.7% |
|
Net Profit |
-- |
$1,029.0 |
$748.0 |
+37.6% |
|
EPS |
$0.72 |
$0.82 |
$0.57 |
+43.9% |
Balance Sheet Highlights (What's this?)
|
Assets |
Q2 2005 |
Q2 2004 |
% Change |
|---|---|---|---|
|
Cash+ ST Invest. |
$4,440.0 |
$4,261.8 |
+4.2% |
|
Inventory |
$984.0 |
$725.1 |
+35.7% |
|
Accounts Rec. |
$1,707.0 |
$1,281.2 |
+33.2% |
|
Liabilities |
|||
|---|---|---|---|
|
Long-Term Debt |
$2,198.0 |
$200.0 |
+999.0% |
|
Accounts Pay.& Accrued Liab. |
$3,178.0 |
$2,099.0 |
+51.4% |
Margin Checkup (What's this?)
|
Q2 2005 |
Q2 2004 |
% Change |
|
|---|---|---|---|
|
Gross Margin |
83.29% |
83.17% |
+0.12% |
|
Op. Margin |
40.76% |
38.96% |
+1.81% |
|
Net Margin |
32.44% |
28.94% |
+3.50% |
Cash Flow Highlights (What's this?)
No cash flow statement provided. (Boo!)
Related Companies:
-
Biogen Idec
(NASDAQ:BIIB) -
Genentech
(NYSE:DNA) -
Genzyme
(NASDAQ:GENZ) -
Gilead
(NASDAQ:GILD) -
Johnson & Johnson
(NYSE:JNJ) -
Pfizer
(NYSE:PFE)
For related Foolishness:
- Amgen recovers some of its luster.
- Rival Genzyme reported results earlier this week.
- Amgen has a drug-approval dilemma.
- Finding biotech's 50-baggers.
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean.
At the time of publication, Nick Baker didn't have a financial position in any company mentioned. Biogen is a recommendation of Motley Fool Stock Advisor, and Pfizer is a pick of Inside Value. View Nick's Fool profile and stock holdingshere. Fool rules arehere.
